Bayer AG
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
-3.31
$46.58B
Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 88,502 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
emptyResult
Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 88,502 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
Recently from Cashu
Bayer AG's Growth Potential from U.S. Defense Production Act Focusing on Herbicide Supply
Bayer AG Poised to Benefit from U.S. Defense Production Act for Herbicides In a decisive move highlighting a shift towards strengthening domestic agricultural production, President Donald Trump signs…
U.S. DPA Boost for Glyphosate and Phosphorus Elevates U.S. Supply Stakes for Bayer AG
U.S. DPA move on glyphosate and phosphorus places strategic spotlight on Bayer AG A presidential order invoking the Defense Production Act to boost domestic supplies of elemental phosphorus and glypho…
Bayer AG presses $10.5 billion plan to resolve Roundup cancer litigation
Bayer presses $10.5 billion plan to resolve Roundup cancer litigation Bayer AG is pushing a $10.5 billion settlement package to resolve current and future U.S. lawsuits alleging its Roundup weedkiller…
Bayer AG proposes $10.5B settlement package to resolve Roundup U.S. cancer lawsuits
Bayer moves to cap Roundup litigation with $10.5 billion settlement package Bayer AG announces a proposed $10.5 billion package to resolve current and future U.S. lawsuits that allege its Roundup weed…